Chen J, et al. – The efficacy and toxicity of combination treatment with intensity–modulated radiotherapy (IMRT) and concurrent chemotherapy with paclitaxel plus different platinum agents had been analysed in locally advanced esophageal squamous cell carcinoma (ESCC). In view of their satisfying therapeutic effects and less toxicity, paclitaxel plus nidaplatinum or lobaplatin was recommended in locally advanced ESCC. Independent prognostic factors in ESCC patients receiving IMRT and concurrent chemotherapy were tumor volume and a maximum diameter of metastatic lymph nodes.

Methods

• 242 patients treated with paclitaxel (135 mg/m2) plus platinum regimens were incorporated in this retrospective study.
• Based on the different platinum agents used, patients were classified into: cisplatin 80 mg/m2 (CP), nidaplatinum 80 mg/m2 (NP), lobaplatin 35 mg/m2 (LP), and oxaliplatin 135 mg m2 (OP) groups.
• In addition, comparison was done for survival and toxicity rates between the four groups.
• It was reported that the median overall survival (OS) was 31.1 months.

Results

• There were no significant differences among the CP, NP, LP, and OP groups with regard to 3-year survival rates (46.2, 56.4, 45.7, and 29.0%, respectively).
• Data depicted significantly lower 3-year survival rates in the OP group.
• As compared to the other three groups, renal toxicities and gastrointestinal reactions were more frequent in the CP group.
• Results found comparable three-year survival rates among patients receiving 2, 3, or ≥4 cycles of chemotherapy (40.1, 49.5, and 50.8%, respectively).
• Tumor volume and maximum diameter of metastatic lymph nodes appeared to be independent prognostic factors.